最新消息
I-Mab Announces Leadership Transitions
2024.07.15
ROCKVILLE, Md. , July 15, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB) (the "Company" or " I-Mab "), a U.S. -based, global biotech company, announced today that the Board of Directors of the Company has appointed Mr. Wei Fu as the Chairman of the Board of Directors. He succeeds Dr. Pamela M.
ROCKVILLE, Md. , June 6, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB ) (the "Company"), a U.S. -based, global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer, today announced the appointment
I-Mab enters clinical collaboration with Bristol Myers Squibb to evaluate Claudin 18.2 x 4-1BB bispecific antibody givastomig in combination with nivolumab and chemotherapy for the treatment of gastric and esophageal cancer. Collaboration builds on promising safety and efficacy data from the